RxSight 3Q 2026: Revenue $24.6M, Net loss $16.2M, EPS ($0.39) — 10-Q Summary

What happened

RxSight reported third-quarter 2026 revenue of $24.6 million, down 19% from a year earlier, and a net loss of $16.2 million, or $0.39 per diluted share. Light Adjustable Lens sales fell by 2,917 units year over year amid increased competition and product-launch trialing; slower device placements led the company to pause manufacturing.

Confirmed

Global impact / market context

Lower lens sales and slower device placements can reduce revenue while leaving manufacturing costs harder to match to demand. The manufacturing pause may limit excess production, but could also constrain supply if demand improves. Higher planned development spending on Alcon lens adaptations adds another potential cost burden.

Analyst inference

The results combine weaker current sales with product development intended to broaden future offerings, including lenses for astigmatism. Investors will weigh whether new designs and lens work can support sales against competition, slower device placements, and increased development spending; the article gives no forecast or timing for a recovery.

Analyst inference

What to watch

1. Watch for subsequent quarterly revenue and lens-sales figures to show whether the 19% revenue decline and lower lens volume persist or begin to ease. Analyst inference
2. Track updates on the manufacturing pause and device placements; the article says slower placements prompted the pause but does not say when production may resume. Analyst inference
3. Look for details on development spending and progress on next-generation LAL, LAL+, Toric, and Alcon lens designs, which could affect future costs and product offerings. Analyst inference

Evidence

• Original source link unavailable